The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma
The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma
复制标题
DOI：
10.1016/j.tvjl.2012.07.013
复制
发表时间：
2013-03-01
影响因子：
2.2
通讯作者：
Tsujimoto, Hajime
中科院分区：
文献类型：
--
作者：
Sato, Masahiko;Yamzaki, Jumpei;Tsujimoto, Hajime
在 36 只患有多中心高级别 B 细胞淋巴瘤的狗中检查了化疗早期微小残留病 (MRD) 的预后意义。扩增来自淋巴瘤细胞的免疫球蛋白重链 (IgH) 基因片段的序列，并用于设计用于实时 PCR 的等位基因特异性引物和探针。这些狗接受威斯康星大学麦迪逊分校化疗方案 (UW-25) 为期 6 个月的修改版治疗，并在 UW-25 的第 6 周和第 II 周评估 MRD 水平。在第 11 周保留方案的 31 只狗中，发现 14 只 MRD 阴性（= 10 个肿瘤细胞/10(5) PBMC）。第 11 周时 MRD 阴性犬的无进展生存期（中位 337 天）显着长于同一时间点 MRD 阳性犬的无进展生存期（中位 196 天）（P = 0.0002）。这些结果表明MRD作为化疗早期预后标志物的临床意义。 (C) 2012 Elsevier Ltd. 保留所有权利。
The prognostic significance of minimal residual disease (MRD) in the early phases of chemotherapy was examined in 36 dogs with multicentric high-grade B-cell lymphoma. Sequences of immunoglobulin heavy chain (IgH) gene fragments from lymphoma cells were amplified and used to design allele-specific primers and probes for real-time PCR. The dogs were treated with a 6-month modified version of the University of Wisconsin-Madison chemotherapy protocol (UW-25) and evaluated for the MRD level at weeks 6 and II of UW-25.Of the 31 dogs that remained on the protocol at week 11, 14 were found to be MRD negative (= 10 tumour cells/10(5) PBMCs). The progression-free survival of the dogs with MRD-negative status at week 11 (median, 337 days) was significantly longer than that of the MRD-positive dogs at the same time point (median, 196 days) (P = 0.0002). These results indicate the clinical significance of MRD as a prognostic marker in the early phase of chemotherapy. (C) 2012 Elsevier Ltd. All rights reserved.